COMMUNIQUÉS West-GlobeNewswire
-
Guidelight Health Opens Eighth Massachusetts Location, Expanding Access to Structured Mental Health Care
22/07/2026 -
Unnatural Products Appoints Finance Leader Neera Ravindran, M.D., M.B.A., as Chief Financial Officer
22/07/2026 -
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
22/07/2026 -
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
22/07/2026 -
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
22/07/2026 -
uniQure to Announce Second Quarter 2026 Financial Results
22/07/2026 -
Specialized Manufacturing Capability Emerges as the New Competitive Advantage in the $23.2 Billion Global Biologics CDMO Market, Finds Alira Health
22/07/2026 -
Cannara Announces Normal Course Issuer Bid
22/07/2026 -
Exubrion Therapeutics Promotes Gregory Taglialatela to Chief Commercial Officer
22/07/2026 -
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
22/07/2026 -
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
22/07/2026 -
VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase
22/07/2026 -
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
22/07/2026 -
Veraify Launches Groundbreaking AI-Native Security Platform Built for the AI Workforce Era
22/07/2026 -
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
22/07/2026 -
SoldierStrong Donates Two Real® Immersive Systems to Palo Alto VA to Advance Veteran Rehabilitation
22/07/2026 -
CMR Surgical and NVIDIA showcase future of intelligent surgery with Versius Plus™ at SRS 2026
22/07/2026 -
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
22/07/2026 -
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
22/07/2026
Pages